Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature
- 1 September 2014
- journal article
- case report
- Published by Elsevier in Human Pathology
- Vol. 45 (9) , 1918-1927
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Science and Technology Agency
- Cornell University
- Medical College, Weill Cornell Medicine
- University of Tsukuba
This publication has 33 references indexed in Scilit:
- New Insights into Molecular Mechanisms of Sunitinib-Associated Side EffectsMolecular Cancer Therapeutics, 2011
- Glomerular Structure and Function Require Paracrine, Not Autocrine, VEGF–VEGFR-2 SignalingJournal of the American Society of Nephrology, 2010
- Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathyNephrology Dialysis Transplantation, 2009
- Nephrotic syndrome caused by the angiogenesis inhibitor sorafenibAnnals of Oncology, 2009
- Nephrotic Syndrome and Acute Renal Failure Apparently Induced by SunitinibCase Reports in Oncology, 2009
- Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinibNephrology Dialysis Transplantation, 2008
- Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic MiceDiabetes, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Thrombotic microangiopathy and anti-VEGF agentsNephrology Dialysis Transplantation, 2007
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006